Clinical Trial

Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

Study acronym: REALM-Post
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC. Based on the inclusion and exclusion criteria, patients with advanced NSCLC who received first-line Tislelizumab treatment and progressed will be retrospectively screened and collected from January 1, 2020, to the study initiation date, and followed up for observation.
Trial Details
NCT Number NCT06962449
Lead Sponsor Shanghai Chest Hospital
Conditions Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV
Enrollment 500 participants
Start Date 2024-08-16
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-08